Is Anuh Pharma the Best Stock in Its Sector? A Look at the Numbers
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Anuh Pharma CMP Rs 93 (23 Sep 2026). Market cap Rs 942 Cr. ROE 11.65%. P/E 21.32x versus Industry P/E 51.81x.
Quick Answer
Anuh Pharma is one of the names investors compare when screening the Healthcare sector, built on a 11.65% return on equity and a P/E of 21.32x against an Industry P/E of 51.81x. Whether Anuh Pharma is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Anuh Pharma the best stock in its sector? The stock trades on the NSE at Rs 93 as of 23 September 2026, within its 52-week range of Rs 67.00 to Rs 99.50. Anuh Pharma Ltd manufactures active pharmaceutical ingredients, particularly antibiotics, for domestic and export markets.
Anuh Pharma sits in the Healthcare sector, and its 11.65% ROE and 21.32x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Anuh Pharma
Anuh Pharma Ltd manufactures active pharmaceutical ingredients, particularly antibiotics, for domestic and export markets. It manufactures active pharmaceutical ingredients, particularly antibiotics such as erythromycin, supplying both domestic and export pharmaceutical markets. At a market capitalisation of Rs 942 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Anuh Pharma the Best Stock in Its Sector?
Anuh Pharma makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 11.65% ROE with a 21.32x P/E against the sector’s 51.81x Industry P/E. Anuh Pharma’s 21.32x P/E is well below the 51.81x Industry P/E despite an 11.65% ROE, making it look inexpensive relative to Alpa Laboratories and the other API and formulation peers used in this series.
| Metric | Anuh Pharma |
|---|---|
| CMP (NSE) | Rs 93.48 |
| 52-Week High / Low | Rs 99.50 / Rs 67.00 |
| Market Cap | Rs 942 Cr |
| P/E (TTM) vs Industry P/E | 21.32x vs 51.81x |
| P/B | 2.68 |
| ROE | 11.65% |
| EPS (TTM) | Rs 4.41 |
| Dividend Yield | 1.60% |
| Debt to Equity | 0.00 |
Compare Anuh Pharma Against Other Healthcare Sector Stocks
How Anuh Pharma Compares Against Its Healthcare Sector Peers
The table below sets Anuh Pharma against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Anuh Pharma | 942 | 21.32 | 11.65% | 0.00 |
| Alpa Laboratories | 128 | 31.43 | 8.06% | 0.01 |
| Bajaj Healthcare | 1,125 | 63.76 | 8.81% | 0.47 |
| Peer average (2 companies) | – | 47.59 | 8.44% | 0.24 |
Against this peer set, Anuh Pharma’s 11.65% ROE is above the 8.44% peer average, and its P/E of 21.32x runs below the peer average of 47.59x. Anuh Pharma’s 21.32x P/E is well below the 51.81x Industry P/E despite an 11.65% ROE, making it look inexpensive relative to Alpa Laboratories and the other API and formulation peers used in this series.
What Makes Anuh Pharma Worth Watching in Healthcare
- Well below Industry P/E: A 21.32x P/E against a 51.81x Industry P/E is a significant discount for an API manufacturer with an 11.65% ROE.
- Debt free balance sheet: A debt to equity ratio of 0.00 gives Anuh Pharma complete flexibility to fund capacity expansion internally.
- Established antibiotic API focus: A long-standing focus on antibiotic APIs such as erythromycin gives Anuh Pharma specialised manufacturing expertise in a regulated product category.
Anuh Pharma Valuation: Is It Justified?
Anuh Pharma’s 21.32x P/E is well below the 51.81x Industry P/E despite an 11.65% ROE, making it look inexpensive relative to Alpa Laboratories and the other API and formulation peers used in this series. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Allied Blenders and Distillers the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Anuh Pharma and other Healthcare sector stocks.
How to Track Anuh Pharma Before You Invest
Before deciding whether Anuh Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Anuh Pharma to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Anuh Pharma earns a place in the best stock in its sector conversation on the strength of a 11.65% ROE and a P/E of 21.32x against a 51.81x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Anuh Pharma the best stock in its sector?
Ans. Anuh Pharma has a 11.65% ROE and trades at 21.32x P/E against a 51.81x Industry P/E, and compares above the peer average ROE of 8.44% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Anuh Pharma?
Ans. Anuh Pharma was trading at Rs 93.48 on the NSE as of 23 September 2026, within its 52-week range of Rs 67.00 to Rs 99.50.
What sector does Anuh Pharma belong to?
Ans. Anuh Pharma is classified under the Healthcare sector on Univest.
How does Anuh Pharma compare to its sector peers on P/E?
Ans. Anuh Pharma’s P/E of 21.32x is below the 47.59x average of the 2 named peers compared in this article.
What is Anuh Pharma’s return on equity?
Ans. Anuh Pharma reported a return on equity of 11.65%, which is above the 8.44% average of its named peers in this comparison.
Should I invest in Anuh Pharma based on its sector position?
Ans. Anuh Pharma’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
